menu

CME: Viewpoints on Managing DR: Addressing Moderate-to-Severe NPDR

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Viewpoints on Managing DR: Addressing Moderate-to-Severe NPDR

Viewpoints on Managing DR: Addressing Moderate-to-Severe NPDR
RestartResume
The treatment paradigm for nonproliferative diabetic retinopathy is shifting. Explore the evidence behind the approach that’s causing this change.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.

    Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    David M. Brown, MD, FACS
    Clinical Professor of Ophthalmology
    Baylor College of Medicine, Houston TX
    Retina Consultants of Houston
    Houston, TX

    Consulting Fees: Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug, Heidelberg, Kodiak, Novartis, Ohr, Optos, Regeneron/Bayer, Regenxbio, Santen, Senju, Stealth Biotherapeutics, Zeiss
    Contracted Research: Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug, Heidelberg, Kodiak, Novartis, Ohr, Optos, Regeneron/Bayer, Regenxbio, Santen, Senju, Stealth Biotherapeutics, Zeiss

    Rishi P. Singh, MD
    Staff Physician
    Cleveland Clinic Cole Eye Institute
    Cleveland, OH

    Consulting Fees: Alcon, Genentech, Novartis, Optos, Regeneron Pharmaecuticals, Zeis
    Contracted Research: Apellis

    Reviewers/Content Planners/Authors: 

    • Rob Braun has nothing to disclose.
    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose. 
    • Robert S. Schneider, MSW has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explore recent evidence for the management of nonproliferative DR with anti-VEGF inhibitors
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists and other eye health professionals.

     

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/14/19